Old Web
English
Sign In
Acemap
>
authorDetail
>
P. Cohen
P. Cohen
University of Rochester
Refractory
Rituximab
Bendamustine
Pathology
Medicine
4
Papers
295
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study
2008
Journal of Clinical Oncology
Jonathan W. Friedberg
P. Cohen
Ling Chen
K. Sue Robinson
Andres Forero-Torres
Ann S. La Casce
Luis Fayad
Alberto Bessudo
Elber S. Camacho
Michael Williams
Richard H. van der Jagt
Jennifer W. Oliver
Bruce D. Cheson
Show All
Source
Cite
Save
Citations (264)
Confirming Changes in Beliefs and Intentions.
2007
AAAI | National Conference on Artificial Intelligence
Rajah Annamalai Subramanian
Sanjeev Kumar
P. Cohen
Show All
Source
Cite
Save
Citations (1)
A phase II, multicenter study of bendamustine HCl plus rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin’s lymphoma (NHL)
2006
Journal of Clinical Oncology
Michael E. Williams
P. Cohen
Anil Tulpule
R. H. Van der Jagt
Jordan A. Herst
Alberto Bessudo
Bernard Lemieux
Lee S. Schwartzberg
Jennifer W. Oliver
Katherine Sue Robinson
Show All
Source
Cite
Save
Citations (21)
The novel alkylator bendamustine HCl is active in both rituximab-refractory and rituximab-sensitive relapsed indolent NHL with acceptable toxicity
2005
Journal of Clinical Oncology
P. Cohen
Bruce D. Cheson
Jonathan W. Friedberg
Katherine Sue Robinson
J. Foran
Luis Fayad
Anil Tulpule
Alberto Bessudo
R. H. Van der Jagt
M. S. Suster
Pratik S. Multani
Show All
Source
Cite
Save
Citations (9)
1